Business
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Mexican Institute of Industrial Property (IMPI) has issued Patent Number 432748, covering key aspects of the Company's breast cancer vaccine technology.
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"Expands global intellectual property coverage in markets with greater late-stage breast cancerdiagnoses and higher triple-negative breast cancer incidence rates","length":161,"tagName":"p","attribs":{}},{"type":"text","content":"New patent will provide IP protection of Breast Cancer Vaccine in Mexico into 2040","length":82,"tagName":"p","attribs":{}},{"type":"text","content":"SAN JOSE, Calif., April 29, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Mexican Institute of Industrial Property (IMPI) has issued Patent Number 432748, covering key aspects of the Company's breast cancer vaccine technology.","length":402,"tagName":"p"},{"type":"image","alt":"Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)","displaySize":"","headline":null,"caption":"Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":119,"url":"https://media.zenfs.com/en/prnewswire.com/3ba55e340de170a9f97c46887c8c8549"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6M64PPpiKuvSoXzSC64m5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMA--/https://media.zenfs.com/en/prnewswire.com/3ba55e340de170a9f97c46887c8c8549","width":400,"height":119}},"href":"https://mma.prnewswire.com/media/602982/ITUS_Corporation_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""This newly issued patent continues the broad international recognition of the novelty and potential of our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue clinical development in the U.S., our growing international patent estate further strengthens our ability to pursue global opportunities and potentially partner with larger pharmaceutical companies for worldwide commercialization."","length":461,"tagName":"p"},{"type":"text","content":"Anixa's breast cancer vaccine, developed in collaboration with Cleveland Clinic, represents a novel approach to the prevention and treatment of breast cancer. Anixa's vaccine is based on immunizing against human α-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types o...